levamlodipine + benazepril

Levamlodipine + benazepril is a fixed-dose combination (FDC) antihypertensive medication that combines a calcium channel blocker (CCB) with an angiotensin-converting enzyme (ACE) inhibitor. Levamlodipine is the pharmacologically active (S)-enantiomer of amlodipine, which acts by inhibiting the influx of calcium ions into vascular smooth muscle and cardiac muscle cells, leading to peripheral vasodilation and reduced blood pressure. Benazepril is a prodrug that is hydrolyzed to its active metabolite, benazeprilat, which inhibits ACE, thereby preventing the conversion of angiotensin I to the potent vasoconstrictor angiotensin II. This dual mechanism provides synergistic blood pressure lowering effects and may improve patient compliance. Jiangxi Shimei Pharmaceutical is a primary developer of this specific combination, particularly in the Chinese market, where it is indicated for the treatment of hypertension.

Other names

levamlodipine maleate + benazepril hydrochlorideS-amlodipine + benazeprillevamlodipine and benazepril